Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Long-Term Debt Repayments (2022 - 2023)

Arcturus Therapeutics Holdings' Long-Term Debt Repayments history spans 2 years, with the latest figure at $20.0 million for Q4 2023.

  • For Q4 2023, Long-Term Debt Repayments rose 566.67% year-over-year to $20.0 million; the TTM value through Dec 2025 reached $20.0 million, changed N/A, while the annual FY2025 figure was $15.0 million, N/A changed from the prior year.
  • Long-Term Debt Repayments reached $20.0 million in Q4 2023 per ARCT's latest filing, down from $27.4 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $27.4 million in Q1 2023 to a low of $3.0 million in Q4 2022.